Another cancer vaccine has shown results in canine osteosarcoma

Share This Post

Scientists at Michigan State University are designing a virus-like particle called Qβ, which will generate an anti-cancer immune response in the body and may be used as a new vaccine for cancer treatment. The US $ 2.4 million project funded by the National Cancer Institute will support the development of vaccines to protect animals from cancer cells that are currently incurable, and may well be a vaccine for spontaneous cancer in humans.

The team will combine Qβ particles with tumor-associated carbohydrate antigens (TACAs), and they believe these antigens will produce complete anti-tumor cell immunity, reduce tumor growth and prevent tumor development. In addition, the researchers will use the crystal structure of Qβ to develop mutations that reduce toxic antibodies and promote the desired cells, which can also kill cancer cells. This is the first such trial using a TACA vaccine model.

This vaccine will be used first to treat canine cancer and will focus on osteosarcoma, which is a refractory dog ​​and human bone tumor.

Vaccines can reduce tumor growth and protect patients from tumor progression and further progress. If we can further understand the relationship between the structural characteristics of Qβ-TACA and anti-tumor immunity, it can have a great effect on the design of cancer vaccines. This research also strengthens the important role of veterinary medicine in cancer research.

Yuzbasiyan-Gurkan said: “Spontaneous cancer in dogs and cats provides a real test for cancer vaccines. This is just one example of the many ways in which veterinary and human medical research can benefit each other.”

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy